Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Financing Activities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Cash from Financing Activities data on record, last reported at -$2.5 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 103.4% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached -$5.9 million, down 107.86%, while the annual FY2025 figure was -$5.9 million, 107.86% down from the prior year.
  • Cash from Financing Activities reached -$2.5 million in Q4 2025 per ACRS's latest filing, up from -$3.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $135.9 million in Q2 2021 and bottomed at -$11.6 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $20.4 million, with a median of -$5500.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 152104.08% in 2024, then tumbled 13936.36% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$2000.0 in 2021, then soared by 1950.0% to $37000.0 in 2022, then soared by 32.43% to $49000.0 in 2023, then surged by 152104.08% to $74.6 million in 2024, then plummeted by 103.4% to -$2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$2.5 million in Q4 2025, -$3.0 million in Q3 2025, and -$9000.0 in Q2 2025.